FDA Grants Platform Tech Designation To Viral Vector In Sarepta's SRP-9003 For LGMD Type 2E/R4

RefinitivMenos de 1 minuto de leitura

Sarepta Therapeutics Inc SRPT:

U.S. FDA GRANTS PLATFORM TECHNOLOGY DESIGNATION TO THE VIRAL VECTOR USED IN SRP-9003, SAREPTA’S INVESTIGATIONAL GENE THERAPY FOR THE TREATMENT OF LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2E/R4

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Entrar ou criar uma conta gratuita para ler essa notícia